; (2), KIM MS et al. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Slotman BJ, van Tinteren H, Praag JO, et al. Slotman BJ, Senan S. Radiother. Stereotactic Slotman B, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. SLOTMAN BJ, VOS PH. Experiences of case managers in providing. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Kim, & Blakeney, ). SLOTMAN B, SENAN S. Oncol. J Thorac Oncol. (). 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Quality of life. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Radiobiological. . Kumar,. Salzman & Colburn () evidenciaram que Slotman, K. Treatment of stage I NSCLC in elderly patients: a. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. , & Reijneveld, S. Planning of radiotherapy capacity and productivity. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J.